PRECISION BIOSCIENCES INC (DTIL) Stock Price, Quote, News and Overview
NASDAQ:DTIL - Nasdaq - US74019P2074 - Common Stock - Currency: USD
DTIL Quote, Performance and Key Statistics
NASDAQ:DTIL (5/9/2025, 8:00:01 PM)
5.13
-0.02 (-0.39%)
The current stock price of DTIL is 5.13 USD. In the past month the price increased by 21.28%. In the past year, price decreased by -51.79%.
DTIL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.55B | ||
| AMGN | AMGEN INC | 12.81 | 142.94B | ||
| GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
| ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
| ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.47 | 17.32B |
Related stock screener links
About DTIL
Company Profile
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 108 full-time employees. The company went IPO on 2019-03-28. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The firm's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The firm's iECURE-OTC program is developed in partnership with iECURE, Inc.
Company Info
PRECISION BIOSCIENCES INC
302 E Pettigrew St Ste A100
Durham NORTH CAROLINA 27701 US
CEO: Matthew Kane
Employees: 108
Phone: 19193145512
PRECISION BIOSCIENCES INC / DTIL FAQ
What is the stock price of PRECISION BIOSCIENCES INC today?
The current stock price of DTIL is 5.13 USD. The price decreased by -0.39% in the last trading session.
What is the ticker symbol for PRECISION BIOSCIENCES INC stock?
The exchange symbol of PRECISION BIOSCIENCES INC is DTIL and it is listed on the Nasdaq exchange.
On which exchange is DTIL stock listed?
DTIL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PRECISION BIOSCIENCES INC stock?
10 analysts have analysed DTIL and the average price target is 21.93 USD. This implies a price increase of 327.49% is expected in the next year compared to the current price of 5.13. Check the PRECISION BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PRECISION BIOSCIENCES INC worth?
PRECISION BIOSCIENCES INC (DTIL) has a market capitalization of 54.12M USD. This makes DTIL a Micro Cap stock.
How many employees does PRECISION BIOSCIENCES INC have?
PRECISION BIOSCIENCES INC (DTIL) currently has 108 employees.
What are the support and resistance levels for PRECISION BIOSCIENCES INC (DTIL) stock?
PRECISION BIOSCIENCES INC (DTIL) has a support level at 5.11 and a resistance level at 5.6. Check the full technical report for a detailed analysis of DTIL support and resistance levels.
Is PRECISION BIOSCIENCES INC (DTIL) expected to grow?
The Revenue of PRECISION BIOSCIENCES INC (DTIL) is expected to decline by -69.62% in the next year. Check the estimates tab for more information on the DTIL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PRECISION BIOSCIENCES INC (DTIL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DTIL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DTIL, evaluating the profitability, health, valuation and growth aspects
- PRECISION BIOSCIENCES INC (DTIL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PRECISION BIOSCIENCES INC (DTIL) Sales and EPS estimates to see what analysts future expectations are.
- PRECISION BIOSCIENCES INC (DTIL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PRECISION BIOSCIENCES INC (DTIL) Insider and Institutional Ownership to learn about the owners and their transactions.
- PRECISION BIOSCIENCES INC (DTIL) Stock Chart to make your own analysis
- PRECISION BIOSCIENCES INC (DTIL) Latest news and press-releases to stay up to date.
Does PRECISION BIOSCIENCES INC (DTIL) stock pay dividends?
DTIL does not pay a dividend.
When does PRECISION BIOSCIENCES INC (DTIL) report earnings?
PRECISION BIOSCIENCES INC (DTIL) will report earnings on 2025-05-12, before the market open.
What is the Price/Earnings (PE) ratio of PRECISION BIOSCIENCES INC (DTIL)?
PRECISION BIOSCIENCES INC (DTIL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).
What is the Short Interest ratio of PRECISION BIOSCIENCES INC (DTIL) stock?
The outstanding short interest for PRECISION BIOSCIENCES INC (DTIL) is 7.01% of its float. Check the ownership tab for more information on the DTIL short interest.
DTIL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DTIL. When comparing the yearly performance of all stocks, DTIL is a bad performer in the overall market: 79.95% of all stocks are doing better.
DTIL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DTIL. DTIL may be in some trouble as it scores bad on both profitability and health.
DTIL Financial Highlights
Over the last trailing twelve months DTIL reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS increased by 99.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.43% | ||
| ROA | 5.25% | ||
| ROE | 12.71% | ||
| Debt/Equity | 0.4 |
DTIL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to DTIL. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -4238.4% and a revenue growth -69.62% for DTIL